MedPath

Trimodal Prehabilitation in Pancreatic Cancer Patients Urdergoing Neoadjuvant Treatment

Not Applicable
Recruiting
Conditions
Pancreatic Neoplasms
Interventions
Combination Product: Trimodal prehabilitation
Registration Number
NCT05722223
Lead Sponsor
Puerta de Hierro University Hospital
Brief Summary

Pancreatic cancer is a disease with a very poor prognosis and less than 10% of these patients live beyond 5 years from diagnosis. Further, it is expected to become the second leading cause of death in the coming years. Today, surgery remains the cornerstone in curing this disease, but the addition of chemotherapy is needed to improve survival. The impact of adjuvant treatment has been previously demonstrated and its efficacy is absolute. However, neoadjuvant chemotherapy (pre-surgery) improves the results after surgery (achieving earlier stages and with better prognosis) and would lead to better survival results. Besides, the moment of cancer diagnosis is a moment of special receptivity to change lifestyles ("teachable moment").

Multimodal prehabilitation includes 1) physical exercise; 2) nutritional and 3) psychological support. The potential advantages of prehabilitation during neoadjuvant therapy would be 1) the possibility of achieving a better physical condition to face surgery; 2) fewer postoperative complications; 3) more likely to receive adjuvant treatment after surgery; 4) better physical function at the end of treatments. To date, most studies have focused on lung and prostate cancer, with a high prevalence of men in the series.

This strategy has previously been explored, showing that it is safe and feasible, (Loughney et al). We have not identified any study of trimodal prehabilitation during neoadjuvant treatment and none that has integrated motivational strategies to maintain adherence.

Patients during chemotherapy have perceived several adverse effects that could limit adherence to the program. In this regard, a review on the motivation and exercise in cancer survivors shows that it is necessary to apply theoretical frameworks to understand cognitive and motivational processes and develop educational interventions. The self-determination theory is one of the motivational theories most applied today to the analysis of factors related to the adoption of healthy lifestyles. Likewise, patients who are motivated are more likely to improve healthy habits and obtain greater adherence to exercise performance. Therefore, we aimed of carrying out an intervention (pilot study) in ten patients to describe the feasibility of a trimodal prehabilitation program in the hospital environment, applying motivational strategies and a mixed-method (face-to-face and online).

Detailed Description

outcome measures refer to feasibility of the intervention:

Recruitment Attendance to the training sessions Attendance to psychologist and nutritionist sessions

And also to physical condition Cardiorespiratory fitness Muscular strength Body composition Physical activity Quality of life Fatigue score

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
10
Inclusion Criteria
  • More than 18 years old
  • ECOG 0-2
  • Being able to complete the mile-time test
  • Stages I-III
  • Being able to understand the informed consent
  • Pancreatic cancer diagnosed
Exclusion Criteria
  • Metastasic cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Training groupTrimodal prehabilitationPancreatic patients will participate in the trimodal prehabilitation: nutrition, psychological and exercise support.
Primary Outcome Measures
NameTimeMethod
To explore the feasibility of a trimodal prehabilitation program in the hospital setting1 year

Adherence to 70% of supervised physical exercise sessions and to nutrition and psychologist sessions

Secondary Outcome Measures
NameTimeMethod
Changes in (estimated) cardiorespiratory fitness3-6 months (from 1st treatment to surgery)

Mile-time test

Changes in muscle strength3-6 months (from 1st treatment to surgery)

Handgrip by dynamometry

Changes in body mass index3-6 months (from 1st treatment to surgery)

BMI (Body Mass Index kg/sm)

Changes in levels of physical activity at week3-6 months (from 1st treatment to surgery)

Accelerometry

Changes in quality of life3-6 months (from before1st treatment to surgery)

EORTC-QLQ-C30 (European Organization for Research and Treatment of Cancer. Quality of Life questionnaire. C30. all scores of the QLQ-C30 were transformed linearly so that all scales ranged from 0 to 100. In the function scales higher scores represent a better level of functioning while in the case of symptom scales/items higher scores mark a higher level of symptomatology or problems.

Describe changes in fatigue levels3-6 months (from before 1st treatment to surgery)

PERFORM (Multidimensional scale 12-60. The higher the less fatigue)

Changes in body composition3-6 months (from 1st treatment to surgery)

waist, hip, calf circumferences

Dose intensity in neoadjuvant treatment3-6 months (from 1st treatment to surgery)

percentage of intended doses that are administered in the due time

Describe post-surgical complicationsthree months

Surgical wound and pancreatic fistula

Nutritional status3-6 months (from 1st treatment to surgery)

body mass index

Percentage of pathological complete responses4-6 weeks after surgery

Percentage of patients with no viable cells in the surgical specimen

Percentage of patients receiving adjuvant therapyThree months after surgery

Patients that received at least two cycles after surgery

Hindrances and facilitators of patientsDuring the prehabilitation program (3-6 months for each patient)

Qualitative methods. semi-structured interviews and observation

Anxiety and depression3-6 months (from 1st treatment to surgery)

Hospital Anxiety and Depression Scale questionnaire. Values 8-21. The higher the worse

Trial Locations

Locations (1)

Hospital Universitario Puerta de Hierro Majadahonda

🇪🇸

Majadahonda, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath